Joshua Jennings
Stock Analyst at TD Cowen
(3.29)
# 966
Out of 4,784 analysts
68
Total ratings
44.44%
Success rate
3.77%
Average return
Main Sectors:
Stocks Rated by Joshua Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVR Anteris Technologies Global | Initiates: Buy | $15 | $3.80 | +294.74% | 1 | Jan 7, 2025 | |
| PODD Insulet | Maintains: Buy | $264 → $324 | $258.75 | +25.22% | 1 | Jan 3, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $100 → $110 | $99.36 | +10.71% | 7 | Dec 12, 2024 | |
| CBLL CeriBell | Maintains: Buy | $31 → $36 | $19.46 | +84.99% | 2 | Dec 9, 2024 | |
| TMDX TransMedics Group | Maintains: Buy | $175 → $120 | $68.58 | +74.98% | 9 | Nov 18, 2024 | |
| HUMA Humacyte | Reiterates: Buy | $10 | $1.96 | +410.20% | 2 | Oct 18, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $50 | $3.20 | +1,462.50% | 1 | Oct 2, 2024 | |
| PRCT PROCEPT BioRobotics | Maintains: Buy | $75 → $99 | $60.05 | +64.86% | 3 | Sep 16, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Hold | $143 → $119 | $112.26 | +6.00% | 1 | Sep 6, 2024 | |
| VCEL Vericel | Maintains: Buy | $55 → $60 | $44.50 | +34.83% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $83 → $80 | $83.62 | -4.33% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $45 | $12.58 | +257.71% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $100 → $70 | $70.91 | -1.28% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $185 | $163.71 | +13.00% | 1 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 | $33.75 | +18.52% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $400 | $364.50 | +9.74% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $40.43 | +48.40% | 4 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $34 | $19.28 | +76.35% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $18 | $6.05 | +197.52% | 3 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $114 → $125 | $67.74 | +84.53% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $25 | $15.95 | +56.74% | 1 | Dec 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 | $130.82 | -0.63% | 9 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $5 | $1.80 | +177.78% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $117 | $87.63 | +33.52% | 3 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $450 | $6.17 | +7,193.35% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $10.19 | +17.76% | 1 | Sep 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $306 → $275 | $227.50 | +20.88% | 1 | Feb 7, 2020 |
Anteris Technologies Global
Jan 7, 2025
Initiates: Buy
Price Target: $15
Current: $3.80
Upside: +294.74%
Insulet
Jan 3, 2025
Maintains: Buy
Price Target: $264 → $324
Current: $258.75
Upside: +25.22%
Boston Scientific
Dec 12, 2024
Maintains: Buy
Price Target: $100 → $110
Current: $99.36
Upside: +10.71%
CeriBell
Dec 9, 2024
Maintains: Buy
Price Target: $31 → $36
Current: $19.46
Upside: +84.99%
TransMedics Group
Nov 18, 2024
Maintains: Buy
Price Target: $175 → $120
Current: $68.58
Upside: +74.98%
Humacyte
Oct 18, 2024
Reiterates: Buy
Price Target: $10
Current: $1.96
Upside: +410.20%
Allurion Technologies
Oct 2, 2024
Initiates: Buy
Price Target: $50
Current: $3.20
Upside: +1,462.50%
PROCEPT BioRobotics
Sep 16, 2024
Maintains: Buy
Price Target: $75 → $99
Current: $60.05
Upside: +64.86%
Zimmer Biomet Holdings
Sep 6, 2024
Maintains: Hold
Price Target: $143 → $119
Current: $112.26
Upside: +6.00%
Vericel
Aug 27, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $44.50
Upside: +34.83%
Aug 13, 2024
Maintains: Hold
Price Target: $83 → $80
Current: $83.62
Upside: -4.33%
Aug 8, 2024
Maintains: Buy
Price Target: $135 → $45
Current: $12.58
Upside: +257.71%
Jul 25, 2024
Downgrades: Hold
Price Target: $100 → $70
Current: $70.91
Upside: -1.28%
Jul 18, 2024
Maintains: Buy
Price Target: $195 → $185
Current: $163.71
Upside: +13.00%
May 10, 2024
Downgrades: Hold
Price Target: $40
Current: $33.75
Upside: +18.52%
Apr 11, 2024
Maintains: Buy
Price Target: $365 → $400
Current: $364.50
Upside: +9.74%
Mar 12, 2024
Maintains: Outperform
Price Target: $50 → $60
Current: $40.43
Upside: +48.40%
Aug 4, 2023
Maintains: Outperform
Price Target: $52 → $34
Current: $19.28
Upside: +76.35%
May 11, 2023
Maintains: Outperform
Price Target: $14 → $18
Current: $6.05
Upside: +197.52%
Feb 10, 2023
Maintains: Outperform
Price Target: $114 → $125
Current: $67.74
Upside: +84.53%
Dec 30, 2022
Maintains: Outperform
Price Target: $6 → $25
Current: $15.95
Upside: +56.74%
Dec 13, 2022
Maintains: Outperform
Price Target: $130
Current: $130.82
Upside: -0.63%
Nov 11, 2022
Maintains: Outperform
Price Target: $7 → $5
Current: $1.80
Upside: +177.78%
May 27, 2022
Maintains: Outperform
Price Target: $125 → $117
Current: $87.63
Upside: +33.52%
Dec 7, 2021
Initiates: Outperform
Price Target: $450
Current: $6.17
Upside: +7,193.35%
Sep 3, 2020
Initiates: Outperform
Price Target: $12
Current: $10.19
Upside: +17.76%
Feb 7, 2020
Downgrades: Market Perform
Price Target: $306 → $275
Current: $227.50
Upside: +20.88%